GlassScriptPhysician profile
Joshua Tinsley
NPI 1407383953
$4,092.28
in general payments reported to CMS, 2019-2025
25 companies · $761 in 2025
The $761 reported for 2025 was more than what 86% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $262 · 2020: $369 · 2021: $506 · 2022: $838 · 2023: $706 · 2024: $649 · 2025: $761.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,116.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,116.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $530.54 | 2019-2025 | Rocklatan, Tryptyr, Eysuvis |
| Abbvie INC. | $503.38 | 2022-2025 | Alphagan P, Lumigan, Durysta |
| Mallinckrodt Hospital Products INC. | $383.65 | 2021-2025 | Acthar |
| Eyevance Pharmaceuticals LLC | $355.51 | 2019-2023 | Flarex |
| Sun Pharmaceutical Industries INC. | $297.45 | 2020-2023 | Cequa |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $266.51 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $245.42 | 2019-2023 | |
| Oyster Point Pharma, INC. | $185.19 | 2022-2024 | Tyrvaya, Ryzumvi |
| Glaukos Corporation | $184.77 | 2019-2023 | Photrexa Cross-Linking Kit |
| Allergan, INC. | $184.70 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $169.60 | 2022-2025 | Xiidra, Vyzulta |
| Aerie Pharmaceuticals, INC. | $129.81 | 2019-2021 | |
| Harrow Eye, LLC | $103.86 | 2025 | Vevye |
| Tarsus Pharmaceuticals, INC. | $96.91 | 2024-2025 | Xdemvy |
| Astellas Pharma US INC | $86.64 | 2023-2025 | Izervay |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $84.49 | 2024-2025 | Vabysmo |
| Sight Sciences, INC. | $54.76 | 2021-2024 | Omni Surgical System |
| Apellis Pharmaceuticals, INC. | $52.65 | 2023 | Syfovre |
| Ani Pharmaceuticals, INC. | $49.25 | 2023-2025 | Purified Cortrophin Gel |
| Mallinckrodt Enterprises LLC | $36.76 | 2019 | |
| Kala Pharmaceuticals, INC. | $24.83 | 2021 | |
| Rxsight INC | $24.08 | 2024 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens |
| Biotissue Holdings INC. | $16.40 | 2021 | |
| Dompe US, INC. | $13.99 | 2025 | Oxervate |
| Eyepoint US, INC. | $11.13 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joshua Tinsley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.